The vote of confidence is a stepping stone for the company to seek 510(k) approval for an H1N1 test on its platform; to tackle the point-of-care diagnostic market; and to further develop tests for other infectious diseases.
The San Antonio-based firm also intends to file a 510(k) for clearance of the assay.
The clearance covers a respiratory viral test for both RSV and hMPV.
Quidel said that Diagnostic Hybrids' fluorescent in vitro diagnostic assays would complement Quidel's point-of-care diagnostics for infectious disease and reproductive health.
The Associated Press reports that gene-edited food may soon be for sale.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.